替卡西林-克拉维酸 | 86482-18-0

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 替卡西林-克拉维酸
• 中文别名: 替门汀
• 英文名称: Ticarcillin-clavulanic acid
• 英文别名: (2S,5R,6R)-6-[[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
• CAS: 86482-18-0
• 化学式: C23H25N3O11S2
• 分子量: 583.6
• InChiKey: XWMVMWTVLSLJGY-FAJPTIRJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.55
• 重原子数：
  39
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  265
• 氢给体数：
  5
• 氢受体数：
  13

ADMET

毒理性

• 在妊娠和哺乳期间的影响

◉ 母乳喂养期间使用总结：有限的信息表明，替卡西林在乳汁中产生的水平较低，预计不会对哺乳婴儿造成不良影响。克拉维酸尚未在哺乳期母亲中进行研究。偶尔有报道使用青霉素会破坏婴儿的胃肠道菌群，导致腹泻或鹅口疮，但这些影响尚未得到充分评估。替卡西林和克拉维酸在哺乳期母亲中是可以接受的。 ◉ 对哺乳婴儿的影响：截至修订日期，没有找到相关的已发布信息。 ◉ 对泌乳和母乳的影响：截至修订日期，没有找到相关的已发布信息。

◉ Summary of Use during Lactation:Limited information indicates that ticarcillin produces low levels in milk that are not expected to cause adverse effects in breastfed infants. Clavulanic acid has not been studied in nursing mothers. Occasionally disruption of the infant's gastrointestinal flora, resulting in diarrhea or thrush have been reported with penicillins, but these effects have not been adequately evaluated. Ticarcillin and clavulanic acid is acceptable is acceptable in nursing mothers. ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)

文献信息

• [EN] PREPARATION AND USE OF PSEUDOPTEROXAZOLE AND PSEUDOPTEROSIN ANALOGS AND DERIVATIVES<br/>[FR] PRÉPARATION ET UTILISATION D'ANALOGUES ET DE DÉRIVÉS DE PSEUDOPTÉROXAZOLE ET DE PSEUDOPTÉROSINE
  申请人：NAUTILUS BIOSCIENCES CANADA INC

  公开号：WO2012139212A1

  公开（公告）日：2012-10-18

  New methods of converting pseudopterosins to pseudopteroxazoles have been developed and used to make several new non-natural pseudopteroxazole analogs. These as well as pseudopterosins and derivatives thereof and prenylated aromatic structural mimics of pseudopterosins/pseudopteroxazoles are shown to display anti-bacterial activity including that against non-replicating mycobacteria, with some exhibiting no or limited toxicity against mammalian cells.

  已经开发出将伪角藻素转化为伪角藻恶唑的新方法，并用于制造多种新的非天然伪角藻恶唑类似物。这些物质以及伪角藻素及其衍生物和伪角藻素/伪角藻恶唑的异戊二烯基芳香结构模拟物显示出抗细菌活性，包括对非复制分枝杆菌的活性，其中一些对哺乳动物细胞没有或仅有有限的毒性。
• [EN] PROCESS FOR THE MANUFACTURE OF AJOENE DERIVATIVES<br/>[FR] PROCÉDÉ DE PRÉPARATION DE DÉRIVÉS D'AJOÈNE
  申请人：UNIV DANMARKS TEKNISKE

  公开号：WO2012076016A1

  公开（公告）日：2012-06-14

  The present invention relates to the compound (E,Z)-ajoene of formula (1) for use in treatment of bacterial infections. Another aspect of the present invention is a composition comprising (E,Z)-ajoene of formula (1) and at least one antibiotic. Yet another aspect of the invention relates to a method for manufacturing (E,Z) ajoene of formula (1) wherein the conformation of the internal C=C- bond can be either E or Z or a mixture thereof, said method comprising reacting allicin of formula (3) with an acid in the presence of a solvent to provide (E,Z ajoene) of formula (1) as defined above. Yet another aspect of the invention is (E,Z)-ajoene of formula 1 obtainable by the method described above.

  本发明涉及化合物（E,Z）-蒜烯（式1）的用途，用于治疗细菌感染。本发明的另一个方面是包含（E,Z）-蒜烯（式1）和至少一种抗生素的组合物。本发明的另一个方面涉及一种制备（E,Z）蒜烯（式1）的方法，其中内部C=C键的构象可以是E或Z或二者的混合物，所述方法包括在溶剂存在下将大蒜素（式3）与酸反应，以提供上述定义的（E,Z蒜烯）（式1）。本发明的另一个方面是通过上述描述的方法获得的（E,Z）-蒜烯（式1）。
• PROCESS FOR THE MANUFACTURE OF AJOENE DERIVATIVES
  申请人：Bjarnsholt Thomas

  公开号：US20140303070A1

  公开（公告）日：2014-10-09

  The present invention relates to the compound (E,Z)-ajoene of formula (1) for use in treatment of bacterial infections. Another aspect of the present invention is a composition comprising (E,Z)-ajoene of formula (1) and at least one antibiotic. Yet another aspect of the invention relates to a method for manufacturing (E,Z) ajoene of formula (1) wherein the conformation of the internal C═C— bond can be either E or Z or a mixture thereof, said method comprising reacting allicin of formula (3) with an acid in the presence of a solvent to provide (E,Z ajoene) of formula (1) as defined above. Yet another aspect of the invention is (E,Z)-ajoene of formula 1 obtainable by the method described above.

  本发明涉及化合物（E，Z）-ajoene的公式（1），用于治疗细菌感染。本发明的另一方面是包含公式（1）的（E，Z）-ajoene和至少一种抗生素的组合物。本发明的另一方面涉及一种制备公式（1）的（E，Z）-ajoene的方法，其中内部C═C—键的构象可以是E或Z或它们的混合物，该方法包括在溶剂存在下反应公式（3）的大蒜素与酸，以提供上述定义的公式（1）的（E，Z）-ajoene。本发明的另一方面是通过上述描述的方法获得的公式1的（E，Z）-ajoene。
• Treating and preventing disease with TMA and TMAO lowering agents
  申请人：The Cleveland Clinic Foundation

  公开号：US10117879B2

  公开（公告）日：2018-11-06

  Provided herein are compositions, systems, and methods for treating a disease, such as kidney and/or cardiovascular disease, with an agent that reduces the production of trimethylamine (TMA) or trimethylamine-n-oxide (TMAO) in a subject. In certain embodiments, the agent is: i) 3,3-dimethyl-1-butanol (DMB) or a DMB derivative or related compound, ii) acetylsalicylic acid or derivative thereof (e.g., with an enteric coating for delivery to the colon and/or cecum); iii) a flavin monooxygenase 3 (FMO3) inhibitor; iv) a gut TMA lyase inhibitor; v) an antibiotic or antimicrobial; vi) a probiotic or prebiotic; vii) an antiplatelet agent; or viii) a TMA and/or TMAO sequestering agent.

  本文提供的组合物、系统和方法用于使用可减少受试者体内三甲胺（TMA）或三甲胺氧化物（TMAO）产生的制剂治疗疾病，如肾脏和/或心血管疾病。在某些实施方案中，药剂是：i) 3,3-二甲基-1-丁醇（DMB）或 DMB 衍生物或相关化合物，ii) 乙酰水杨酸或其衍生物（例如、iii) 黄素单加氧酶 3 (FMO3) 抑制剂；iv) 肠道 TMA 裂解酶抑制剂；v) 抗生素或抗菌剂；vi) 益生菌或益生元；vii) 抗血小板剂；或 viii) TMA 和/或 TMAO 封闭剂。
• Topical treatments incorporating Cannabis sp. derived botanical drug product
  申请人：Sekura Ronald D.

  公开号：US10226496B2

  公开（公告）日：2019-03-12

  A topical formulation comprising a Cannabis derived botanical drug product, wherein the concentration of tetrahydrocannabinol, cannabidiol, or both in the topical formulation is greater than 2 milligrams per kilogram.

  一种由大麻提取的植物药产品组成的外用制剂，其中外用制剂中四氢大麻酚、大麻二酚或二者的浓度大于每公斤 2 毫克。